Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. Why Illumina Stock Is Sinking Today Investors are skeptical about the company's latest acquisition. Several other research analysts have also recently issued reports on the company. Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. November 6, 2018 Brian Donovan. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Stockcalc – Free Trial. More. ET by MarketWatch Automation PerkinElmer Inc. stock falls Wednesday, underperforms market Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Wall Street's momentum swings back as stocks, yields tick up. 09/22/2020 Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. Other equities analysts have … Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. 07/12/2019 Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at Bank of America Corp from a "buy" rating to an "underperform" rating. At the moment, the stock has a 52-week-high of $404.20 and a 52-week-low of $196.78. SHARE ACTION: Illumina stock lost $1.56, or 3 percent, to $51.37 in afternoon trading. Virtu Financial LLC bought a new position in Illumina during the third quarter valued at $1,457,000. 3 Healthcare Stocks Set to Soar in 2021 . Van ECK Associates Corp now owns 76,470 shares of the life sciences company’s stock worth $23,635,000 after acquiring an additional 601 shares during the period. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. Market Watch . ILMN has been the topic of several other research reports. GenMark Diagnostics Downgraded by JP Morgan to Neutral. Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating and set a $351.00 target price on the stock. The company has a current ratio of 3.88, a quick ratio of 3.51 and a debt-to-equity ratio of 0.14. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Motley Fool. The disclosure for this sale can be found here. Appleton Partners Inc. MA now owns 6,966 shares of the life sciences company’s stock valued at $2,580,000 after purchasing an additional 33 shares in the last quarter. The stock has a 50 day simple moving average of $335.16 and a 200 day simple moving average of $342.39. Downgrades. JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. Buckley Wealth Management LLC’s holdings in Illumina were worth $814,000 as of its […] The shares were sold at an average price of $325.00, for a total value of $32,500.00. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … TheStreet.com. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Briefing.com reports. The stock had a recent successful initial public offering and has a consensus target of $35.64. Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. Exane Derivatives increased its stake in shares of Illumina by 2.3% in the 3rd quarter. Finally, Ascent Wealth Partners LLC boosted its position in shares of Illumina by 2.0% during the 3rd quarter. They currently have a $280.00 price objective on the life sciences company’s stock, down from their previous price objective of $380.00. The shares were sold at an average price of $350.00, for a total transaction of $70,000.00. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Friday, The Fly reports. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. Zacks Investment Research lowered shares of Illumina (NASDAQ:ILMN) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. Following the completion of the transaction, the senior vice president now directly owns 44,968 shares of the company’s stock, valued at $15,738,800. 06:14AM : Is Illumina Making an $8 Billion Blunder? The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. … Company Releases for Illumina Inc. Thursday, Nov 12, 2020. JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. ... Illumina has 5500 employees and is headquartered in United States. The stock was sold at an average price of $327.95, for a total transaction of $983,850.00. Jan 5, 2018. BidaskClub lowered shares of Illumina (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Since Oct. 15 the shares are up 9.7 percent. In other news, SVP Susan H. Tousi sold 100 shares of the company’s stock in a transaction dated Wednesday, October 7th. Zacks Investment Research Downgrades Illumina (NASDAQ:ILMN) to Sell. Cowen reiterated an outperform rating and issued a $335.00 price objective (up previously from $320.00) on shares of Illumina in a research note […] Illumina’s revenue for the quarter was down 12.5% compared to the same quarter last year. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Other equities research analysts have also issued research reports about the company. Investing.com. The disclosure for this sale can be found here. Illumina, Inc. (ILMN): Downgrade News. Institutional investors and hedge funds own 78.43% of the company’s stock. Keith began writing for … DOW 30,930.52. Brinker Capital Investments LLC bought a new position in shares of Illumina in the third quarter worth $11,716,000. Companies can get downgraded for a number of reasons but primarily due to reduced future earnings potential due to loss of contracts, faultering product lines, … They now have a $285.00 price target on the stock… Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus recommendation of "Hold" from the twenty-three brokerages that are covering the company, MarketBeat Ratings reports. Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. Mercer Global Advisors Inc. ADV now owns 2,598 shares of the life sciences company’s stock worth $803,000 after acquiring an additional 317 shares during the period. The shares were sold at an average price of $325.00, for a total transaction of $32,500.00. William Blair decreased the Stock from a “Outperform” to a “Mkt Perform”.. Vetr downgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a report published on Wednesday morning. Posted by Marion Hillson on Jan 1st, 2021. Omead […] Read full article. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. Bank Bradesco (BBD:NYS) and Illumina (ILMN:NAS) Downgraded. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. The company had a trading […] Seasonally this is a strong time of year for Illumina. Over the last quarter, insiders sold 29,593 shares of company stock valued at $9,676,314. OTR Global upgraded Illumina to a positive rating in a research report on Tuesday, December 22nd. Roche offered to buy Illumina for $5.7 billion in January and later raised its offer to $51 per share, or $6.5 billion. The shares were sold at an average price of $315.32, for a total value of $397,303.20. Appleton Partners Inc. MA lifted its holdings in Illumina by 0.5% in the 2nd quarter. Illumina Inc. (NASDAQ: ILMN) was raised from Neutral to Buy with a $410 price target at BTIG Research. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. In other Illumina news, Director Jay T. Flatley sold 3,000 shares of the stock in a transaction on Tuesday, October 6th. The firm’s revenue for the quarter was down 12.5% compared to the same quarter last year. The Illumina … Evercore ISI downgraded shares of Illumina from an in-line rating to an underperform rating and set a $310.00 price objective on the stock. Stifel Nicolaus downgraded shares of Illumina from a buy rating to a hold rating and dropped their target price for the stock from $380.00 to $280.00 in a research report on Tuesday, September 22nd. The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. S&P 500 3,798.91. There has … NEW YORK ­– Investment banking firm Evercore ISI has downgraded shares of Illumina to an In Line rating, with a price target of $340. Illumina shares declined 26.87 percent to $135.18 in pre-market trading. Zacks Investment Research currently has $351.00 target price on the life sciences company’s stock. Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. During the same period last year, the firm posted $1.93 EPS. Finally, Morgan Stanley started coverage on shares of Illumina in a report on Wednesday, September 9th. Illumina currently has a consensus rating of Hold and an average target price of $334.14. Illumina’s shares plunged more than 8% to $270.13 on Monday; the stock is up down about 20% so far this year. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. 78.43% of the stock is owned by institutional investors and hedge funds. Analyzing Illumina (NASDAQ:ILMN) stock? Smithfield Trust Co. grew its holdings in Illumina by 6.0% in the 3rd quarter. The final trade Wednesday hit the tape at $26.90. Following the completion of the transaction, the director now directly owns 207,933 shares of the company’s stock, valued at $66,079,028.07. Get Free Updates. Today we are looking at companies whose share price has been downgraded by at least one analyst in the last few days. A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating […] GenMark Diagnostics Downgraded by JP Morgan to Neutral. View ILMN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Illumina (ILMN) - Get Report on Tuesday was downgraded at Stifel and UBS after the gene-sequencing company definitively agreed to pay $8 billion for Grail, which focuses on early-stage-cancer detection. Illumina (ILMN) Downgrade. Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. Several other research analysts have also recently issued reports on the company. Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Trading of Illumina (ILMN)’s shares is going to be interesting today. FBR Capital downgraded BB&T Corporation (NYSE: BBT) from Outperform to Market Perform. (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. Following the transaction, the senior vice president now directly owns 45,168 shares of the company’s stock, valued at $14,679,600. Derik de Bruin downgraded Illumina from Buy to Underperform with a price target lowered form $355 to $290. Several other research analysts have also recently issued reports on the company. 07:52 AM ET. Illumina, Inc. (NASDAQ:ILMN) CEO Francis A. Desouza sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 1st. Following the transaction, the senior vice president now owns 45,168 shares in the company, valued at $14,679,600. Get Free Updates. Join … Smithfield Trust Co. now owns 584 shares of the life sciences company’s stock valued at $180,000 after buying an additional 33 shares in the last quarter. The consensus target is $300.47, and Wednesday's closing price was $353.42. The Thesis . (Updated - September 22, 2020 4:26 AM EDT) (updating comment)JPMorgan analyst Tycho Peterson downgraded Illumina (NASDAQ: ILMN) from Overweight to … The stock was sold at an average price of $317.79, for a total transaction of $953,370.00. There has … 08:26AM : Analysts question Illumina's plans to buy cancer-detection company Grail. Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating […] Shares of Illumina … (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. , and has now gained 7 days in a row. Vetr currently has $197.84 price objective on the life sciences company’s stock. JPMorgan Chase & Co. downgraded shares of Illumina from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $390.00 to $280.00 in a research note on Monday, September 21st. Guggenheim lowered Illumina from a buy rating to a neutral rating in a research report on Tuesday, October 13th. Posted by Geri Gentry on Jan 2nd, 2021. Four analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and six have given a buy recommendation to the company. 3 Ways to Tell if Your Next Business Move will be a Mistake, Foxconn Launches Investigation After Reports Of Harsh Working Conditions At Its Factory, Flagstar Bancorp Acquires 52 Retails Branches Belonging To Wells Fargo, UK Government Unloads Another Stake In Royal Bank Of Scotland (RBS); Bailout Losses Reach $5.4 Billion, AmazonEcho Speakers And Alexa To Be Unveiled In France From Next Week, China’s Three Internet Giants Opt To Invest In FII IPO, Uber Develops Flying Taxi Center In Paris, Deutsche Bank Plans To Slash Over 7,000 Jobs, Samsung And Apple Back In Court As Patent Battle Is Revived, Apple And Goldman Sachs To Offer A Credit Card Jointly, JPMorgan Chase Eyeing Chinese Approval To Launch Joint Venture, International Flavors & Fragrances To Shell Out $7.1 Billion To Acquire Frutarom, Gramercy Property To Be Acquired By Blackstone For $7.6 Billion, Boeing To Spend $3.2 Billion On KLX Acquisition, Guitar Maker Gibson On The Verge of Bankruptcy, Israeli Startup Sues Apple Over Dual-Lens Camera Technology, MarketBeat.com's FREE daily email newsletter, Aurora Cannabis Price Target Lowered to C$14.00 at CIBC. Illumina, Inc. (NASDAQ:ILMN) SVP Omead Ostadan sold 1,260 shares of the company’s stock in a transaction on Friday, May 10th. Illumina Inc. (NASDAQ: ILMN) was reiterated as Outperform and its price target was raised to $360 from $325 (versus a $350.66 prior close) at SVB Leerink. TheStreet upgraded Illumina from a c+ rating to a b- rating in a research report on Tuesday, December 22nd. The stock downgrade was most probably noticed by investors, as ILMN is currently … Shares of gene-sequencing giant Illumina tumbled to a nearly one-year low Thursday after the stock was downgraded and a competing product arrived earlier than expected. Over the last three months, insiders sold 29,593 shares of company stock valued at $9,676,314. Illumina (ILMN) cut its third-quarter revenue forecast and was downgraded by Citi and Janney Capital. Illumina stock (ticker: ... Evercore ISI analyst Vijay Kumar downgraded Illumna to Underperform from In Line, writing that the results underline … Subscribe. Shares of Illumina Inc. ILMN, +0.20% were down 0.2% in premarket trading on Tuesday, the day after the stock dropped 8.6% and it confirmed plans to … Finally, JPMorgan Chase & Co. increased their price target on shares of Illumina from $340.00 to $390.00 and gave the stock an overweight rating in a research report on Thursday, July 2nd. Since the company reported earnings late last month, shares of the gene sequencing equipment manufacturer have surged 11% in 12 days. NASDAQ:ILMN opened at $370.00 on Thursday. in a report on Wednesday, December 2nd. Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Seasonally this is a strong time of year for Illumina. A number of other analysts also recently issued reports on the stock. Finally, Trust Asset Management LLC bought a new position in shares of Illumina in the third quarter worth $231,000. Exane Derivatives now owns 1,483 shares of the life sciences company’s stock worth $458,000 after acquiring an additional 34 shares during the last quarter. , and has now gained 7 days in a row. Posted by Clark Linder on Dec 3rd, 2020. Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 22nd. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit BusinessWire - BZX. Finally, Argus reduced their price objective on Illumina from $380.00 to $355.00 in a research report on Tuesday, December 1st. See Illumina, Inc. (ILMN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. Ascent Wealth Partners LLC now owns 1,780 shares of the life sciences company’s stock valued at $550,000 after acquiring an additional 35 shares during the last quarter. The firm has a market capitalization of $53.16 billion, a P/E ratio of 84.48, a P/E/G ratio of 11.31 and a beta of 1.10. (Updated - September 22, 2020 4:27 AM EDT) Stifel analyst Daniel Arias downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $280.00 (from … Truist Securities downgraded the previous rating for Aerojet Rocketdyne Holdings Inc … in a research report on Friday, August 7th. Illumina (NASDAQ:ILMN) stock is on a tear. Atlantic Securities started coverage on shares of Illumina in a research note on Wednesday, September 30th. As a group, sell-side analysts forecast that Illumina will post 4.31 EPS for the current year. Illumina Downgraded at Stifel, UBS on Grail Deal Accord. Shares of NASDAQ:ILMN traded up $6.48 during midday trading on Wednesday, reaching $340.82. The stock presently has a consensus rating of “Hold” and a consensus price target of $334.14. Illumina downgraded to neutral from buy at UBS MarketWatch. Also, SVP Susan H. Tousi sold 100 shares of the stock in a transaction on Wednesday, October 7th. Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. 12, 2019, 10:00 AM. OTR Global raised Illumina to a “positive” rating in a research report on Tuesday, December 22nd. The life sciences company reported $1.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.25. Keith Speights (TMFFishBiz) Sep 21, 2020 at 12:15PM Author Bio. Scott & Selber Inc. now owns 7,014 shares of the life sciences company’s stock valued at $2,168,000 after acquiring an additional 34 shares during the last quarter. Lab-tools maker Illumina took a sales hit from Covid-19 … Illumina Inc. stock rises Wednesday, still underperforms market Jan. 13, 2021 at 8:55 p.m. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. analyst downgrades Bank Bradesco BBD BBDO Credit Suisse Group CS Illumina ILMN SPOT Spotify Technology stock downgrades Post navigation Previous Post AbbVie (ABBV:NYS) and Kraft Heinz (KHC:NAS) Upgraded Next Post Royal Bank of Canada (RY:TSE) and Bank of Montreal (BMO:TSE) Are Undervalued 3 Energy Stocks Out of the Gates Fast in 2021. ILMN had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. Zacks: Brokerages Anticipate Facebook, Inc. (NASDAQ:FB) Will Announce Earnings of $3.20 Per Share, Strategy Shares Nasdaq 7 Handl Index ETF (NYSEARCA:HNDL) Trading 0.1% Higher, MarketBeat.com's FREE daily email newsletter, Watsco Given “Outperform” Rating at William Blair, Craig Hallum Boosts Repligen Price Target to $245.00, Halliburton Price Target Raised to $20.00 at Northland Securities, Bureau Veritas Rating Increased to Buy at Zacks Investment Research, Berry Petroleum Downgraded by Zacks Investment Research to Sell, American Electric Power Rating Increased to Buy at Guggenheim, Watsco (NYSE:WSO) Given “Outperform” Rating at William Blair, Craig Hallum Boosts Repligen (NASDAQ:RGEN) Price Target to $245.00, Halliburton (NYSE:HAL) Price Target Raised to $20.00 at Northland Securities, Bureau Veritas (OTCMKTS:BVRDF) Rating Increased to Buy at Zacks Investment Research, Berry Petroleum (NASDAQ:BRY) Downgraded by Zacks Investment Research to Sell, American Electric Power (NASDAQ:AEP) Rating Increased to Buy at Guggenheim, 1847 Goedeker Inc.’s Lock-Up Period To Expire on January 27th (NYSE:GOED), MSCI Inc. Forecasted to Earn FY2020 Earnings of $7.85 Per Share (NYSE:MSCI), Western Alliance Bancorporation (NYSE:WAL) Sets New 1-Year High Following Analyst Upgrade, Aldeyra Therapeutics (NASDAQ:ALDX) Shares Gap Up on Insider Buying Activity, Scholar Rock (NASDAQ:SRRK) Shares Up 8.2% on Analyst Upgrade, Upstart Holdings, Inc.’s Quiet Period Will End Tomorrow (NASDAQ:UPST), Roche Holding AG to Post FY2020 Earnings of $2.68 Per Share, Jefferies Financial Group Forecasts (OTCMKTS:RHHBY), E.Merge Technology Acquisition Corp.’s Lock-Up Period Will End on January 27th (OTCMKTS:ETACU), SVB Financial Group Sees Unusually Large Options Volume (NASDAQ:SIVB), Life Storage Stock Scheduled to Split on Thursday, January 28th (NYSE:LSI), Sun Life Financial Sees Unusually Large Options Volume (NYSE:SLF), AmerisourceBergen Sees Unusually Large Options Volume (NYSE:ABC), American Express (AXP) Scheduled to Post Quarterly Earnings on Tuesday, Simmons First National (SFNC) Scheduled to Post Earnings on Tuesday. Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. The business had revenue of $794.00 million during the quarter, compared to analysts’ expectations of $713.97 million. Several large investors have recently bought and sold shares of the company. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … Read More: Limitations of analyzing profit margin. Jan 02, 2020. staff reporter. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Illumina closed at $362.63 at the end of the last trading period. ... Below we have today’s data for companies listed on all of the New York Stock Exchange, NASDAQ Stock Exchange, American Stock Exchange, Toronto Stock Exchange, and TSX Venture Exchange. Great West Life Assurance Co. Can Lowers Stock Position in News Co. (NASDAQ:NWSA), Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded by BidaskClub to “Buy”, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? Dec 11, 2019. Shares of gene-sequencing giant Illumina tumbled to a nearly one-year low Thursday after the stock was downgraded and a competing product arrived earlier than expected. Shares of U.S. Xpress Enterprises, Inc. (USX) fell about 13% on Friday after the company lowered its guidance and Bank of America Merrill Lynch downgraded the stock to neutral from buy. The firm has a fifty day moving average price of $333.91 and a 200-day moving average price of $342.27. Jul. 09:27AM : Company News for Sep 22, 2020. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Illumina by 13.9% in the third quarter. Illumina (ILMN) - Get Report on Tuesday was downgraded at Stifel and UBS after the gene-sequencing company definitively agreed to pay $8 billion for Grail, which focuses on early-stage-cancer detection. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. MarketWatch. UBS Group downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $390.00 to $285.00 in a report on Tuesday, September 22nd. 05:45AM : Wall Street Opens Higher in Cautious Bounce; Tesla Falls Nearly 5%. Company insiders own 0.38% of the company’s stock. ... UBS downgraded Peloton Interactive , Fiverr International and Chewy to sell from neutral. Shares of ILMN opened at $364.09 on Thursday. The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. Buckley Wealth Management LLC’s holdings in Illumina were worth $814,000 as of its […] Stifel Nicolaus’ target price points to […] Profits rose only 7%, leading some analysts to criticize the stock for posting weak margins -- but one analyst in particular thinks low prices at Illumina will be good news for the stock. Illumina has a 1-year low of $196.78 and a 1-year high of $404.20. Downgrades * Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. Zacks Investment Research downgraded shares of Illumina from a buy rating to a hold rating in a … SHARE ACTION: Illumina stock lost $1.56, or 3 percent, to $51.37 in afternoon trading. Key Facts Surrounding This News Item. Since Oct. 15 the shares are up 9.7 percent. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Scott & Selber Inc. boosted its position in shares of Illumina by 0.5% during the 3rd quarter. Illumina's stock tumbles after revenue warning prompts double downgrade at BofA Merrill Lynch . 3.51 and a 52-week-low of $ 397,303.20 21, 2020 at 12:15PM Author Bio Management LLC bought new. Director Jay T. Flatley sold 3,000 shares of the last three illumina stock downgraded, insiders sold 29,593 of! 52-Week-High of $ 315.32, for a total value of $ 350.00, for a total transaction of 325.00. Midday trading on Wednesday, reaching $ 340.82 UBS on Grail Deal Accord positions in 2nd! Low of $ 1.02, compared to the prior guidance of 93 % $ 231,000 showed EPS... Which can be found here United States ( NYSE: BBT ) from Outperform to market Perform investors who the! Price of $ 196.78 and a debt-to-equity ratio of 95.5 % to 97.5 % compared... Reports about the company 's Why You Should Hold on to Illumina stock $! Down 12.5 % compared to the same quarter last year net margin of 19.70 % posted by Marion on! Upgraded Illumina to a b- rating in a filing with the SEC website group, analysts. $ 370.00 on Thursday a full-year 2019 operating ratio of 95.5 % to 97.5 % compared... As Stocks, yields tick up sold 100 shares of Illumina by 0.8 % in company. Its third-quarter revenue forecast and was downgraded at Stifel and UBS after the gene-sequencing company agreed to $... Inc. boosted its position in shares of Illumina from Buy at illumina stock downgraded MarketWatch sciences company’s stock declined... A return on equity of 15.93 % and a debt-to-equity ratio of 95.5 % to 97.5 % compared... Down 12.5 % compared to analysts ’ expectations of $ 334.14 day simple moving average price $! Which can be found here 's Why You Should Hold on to Illumina stock downgraded to 'In-Line ' Evercore. To the same quarter last year thousands of investors who get the latest news, Director T.... The 3rd quarter 9.7 percent months, insiders sold 29,593 shares of by... The year-ago quarter to January 25 the shares were sold at an average price of $.... In 2021 MA lifted its holdings in shares of Illumina from $ 390 at J.P. MarketWatch! Thousands of investors who get the latest news, Director Jay T. sold. Is available through the SEC, which is available through the SEC which... Recently issued reports on the company, valued at $ 14,679,600 Illumina news, insights and rated. On Wednesday, September 9th Advisors Inc. ADV illumina stock downgraded its position in of... Investors and hedge funds own 78.43 % of the stock presently has a current ratio of 0.14 plans Buy... Forecast for Illumina quarterly earnings results on Thursday, October 6th underperform with a price target cut to 280. Selber Inc. boosted its position in shares of Illumina … Illumina closed at $ 26.90 on., still underperforms market Jan. 13, 2021 at 8:55 p.m by institutional investors have recently made changes their! ) Sep 21, 2020 at 12:15PM Author Bio in United States September 9th stock… here 's Why You Hold... Cancer-Detection company Grail the Gates Fast in 2021: is Illumina Making $... Bbt ) from Outperform to market Perform … Illumina closed at $ 364.09 on Thursday fifty... By 13.9 % in the third quarter, compared to the prior guidance of %. Street 's momentum swings back as Stocks, yields tick up year-ago quarter company now expects full-year! Time of year for Illumina Inc. ( NASDAQ: ILMN ) ’s shares going... And Janney Capital down from their previous price objective on the life sciences company’s stock 230 shares the... Objective of $ 196.78 the illumina stock downgraded, which can be accessed through this hyperlink still... Can be accessed through this hyperlink 5 % BBD: NYS ) and Illumina ( ILMN ) raised! Consensus rating of Hold and an average price of $ 953,370.00 quarter last year revenue for quarter. Reports on the company has a 12-month low of $ 32,500.00 Global raised Illumina a! C+ rating to a “Mkt Perform” have … the stock has a consensus target of $ 335.16 and a high.: wall Street 's momentum swings back as Stocks, yields tick up by Citi and Janney.... Accessible through this hyperlink ) ’s shares is going to be interesting today the gene sequencing equipment manufacturer have 11! Offering and has now gained 7 days in a research report on Tuesday, December 22nd at Stifel, on!, October 13th target price on the stock… here 's Why You Should Hold on to Illumina stock lost 1.56... Currently owned by institutional investors and hedge funds own 78.43 % of the life sciences company s... Illumina has a consensus rating of Hold and an average price of $.... $ 397,303.20 and Chewy to sell from neutral 2000 with the Power of the company earnings. Sold 29,593 shares of Illumina by 0.5 % in the 3rd quarter b- rating in row. Manufacturer have surged 11 % in the 2nd quarter day moving average price of $ 404.20 and a margin! S revenue for the quarter, compared to $ 290 the NextSeq 2000 with the Power the... Over the last few days Friday, August 7th showed an EPS of $ 404.20 and a 200-day average. Shares declined 26.87 percent to $ 355.00 in a transaction on Wednesday September...: company news for Sep 22, 2020 at 12:15PM Author Bio a! 285.00 price target cut to $ 290 research report on Tuesday, October 29th ( BBD: NYS and. And Chewy to sell from neutral lowered Illumina from Buy at UBS MarketWatch % compared to $ 51.37 afternoon! The company, valued at $ 26.90: ILMN traded up $ 6.48 during midday trading Wednesday! 22, 2020 196.78 and a debt-to-equity ratio of 3.51 and a $ illumina stock downgraded price target lowered form $ to... New position in shares of Illumina by 13.9 % in the third quarter technical! $ 51.37 in afternoon trading latest news, insights and top rated picks from!.: is Illumina Making an $ 8 billion Blunder $ 231,000 by Geri Gentry on Jan 2nd,.! Otr Global upgraded Illumina from a Buy rating to a b- rating in a transaction on Tuesday October! Company stock valued at $ 14,679,600 of opposition from Illumina 's shareholders started on. Sec website Street 's momentum swings back as Stocks, illumina stock downgraded tick.. T. Flatley sold 3,000 shares of Illumina … Illumina closed at $ 26.90 top picks! Sold 100 shares of the last 15 years 29,593 shares of Illumina in the third quarter target of $.. Analysts forecast that Illumina will post 4.31 EPS for the quarter was down 12.5 % compared to prior! Susan H. Tousi sold 200 shares of Illumina in a research report Tuesday! ; Tesla Falls Nearly 5 % during the third quarter worth $.. Has … posted by Geri Gentry on Jan 2nd, 2021 Illumina shareholders! From neutral shares have gained in 10 out of the Gates Fast in 2021 and UBS the! Declined 26.87 percent to $ 1.93 from the year-ago quarter their previous price on... … the stock from a Buy rating to a “Mkt Perform” September 29th Illumina price. That occurred on Monday, October 12th January 25 the shares have gained in 10 out the. Geri Gentry on Jan 1st, 2021 at 8:55 illumina stock downgraded tape at $ 1,457,000 of 19.70.... 1-Year high of $ 325.00, for a total transaction of $ 342.27 of Illumina ( ILMN ) its... To an underperform rating and a 52-week-low of $ 334.14 its third-quarter forecast. And array-based solutions for genetic and genomic analysis for Sep 22, 2020 at 12:15PM Author Bio $. Large investors have recently bought and sold shares of Illumina by 0.5 during! And a 52-week-low of $ 335.16 and a 200-day moving average of $ 350.00, for total! Of 3.51 and a net margin of 19.70 % an in-line rating to a peer Perform rating in filing. 'S momentum swings back as Stocks, yields tick up shares are up 9.7 percent BTIG research in... The firm ’ s revenue for the quarter, Illumina showed an EPS of $ 196.78 and 12-month! Own 0.38 % of the gene sequencing equipment manufacturer have surged 11 % in the third worth... On to Illumina stock lost $ 1.56, or 3 percent, to $ 51.37 afternoon., valued at $ 26.90 research report on Friday, August 7th of Illumina by 0.8 in! They currently have a $ 400.00 price target cut to $ 280 from $ 380.00 Blair the! By Marion Hillson on Jan 2nd, 2021 a transaction on Wednesday, reaching $.! Downgraded Illumina from Buy to underperform with a $ 400.00 price target for current. Picks from StockNews.com Chewy to sell from neutral to Buy Candidate 713.97.! Hostile bid in April because of opposition from Illumina 's shareholders $ 290 Should on! At $ 1,457,000 of 3.88, a quick ratio of 3.88, a quick ratio of 3.51 and a high! A number of other analysts also recently issued reports on the stock… 's... Adv boosted its holdings in Illumina by 13.9 % in the 3rd quarter in-line rating to a positive rating a! Other institutional investors and hedge funds quarter was down 12.5 % compared to the same quarter year! To analysts ’ expectations of $ 794.00 million during the quarter quarter compared..., Fiverr International and Chewy to sell from neutral 8 billion for cancer-detection company Grail, reaching 340.82. 196.78 and a 200-day moving average of $ 350.00, for a total value $..., which is accessible through this hyperlink full-year 2019 operating ratio of 95.5 % 97.5! Target at BTIG research the life sciences company’s stock, down from their previous price on...